Delay to Diagnosis in Digestive Cancerology by the General Practitioner Related to Covid-19 Pandemic Confinement

Advanced Cancer Clinical Trial

Official title:

Delay to Diagnosis and Management in Digestive Cancerology by the General Practitioner Within the City-hospital Network in the Context of Confinement Related to the Covid-19 Pandemic

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT06118125
• Other study ID #: 2023-A02271-44
• Status: Completed
• Start date: June 1, 2019
• Est. completion date: September 1, 2022

Study information

• Verified date: November 2023
• Source: University of Bordeaux
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Objective: the pre-hospital management of cancers is little known in General Medicine. The first lockdown related to the COVID-19 pandemic led to the closure of health facilities. Investigators were interested in the diagnosis and care pathway of digestive cancers in post-confinement in General Medicine in Nouvelle-Aquitaine.

Description:

Method: patient records discussed in Digestive Oncology CPR of Bordeaux University Hospital for the first time from June 1 to August 31, 2020 and over the same period in 2019 were included. A questionnaire on the dates of the first symptoms, first consultation with the general practitioner, imaging examination and access to the specialist was sent to the general practitioner. The primary outcome was time from onset to date of first MDT.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 376
• Est. completion date: September 1, 2022
• Est. primary completion date: September 1, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• residing in New Aquitaine and
• whose general practitioner practiced in New Aquitaine
• malignant tumors of the esophagus, stomach, small intestine, colon, recto-sigmoid junction, rectum, anus and anal canal, liver and intrahepatic bile ducts, extrahepatic bile ducts, gallbladder and pancreas.
• to have had at least one consultation or hospitalization in the digestive pole of the Bordeaux University Hospital within 6 months after the MDT.

Exclusion Criteria:

• Patients under 18 years of age,
• who had already had a MDT for this cancer,
• whose date of first MDT was outside the inclusion dates,
• whose new cancer was a digestive metastasis of a primary of another location,
• who did not have French health insurance

Related Conditions & MeSH terms

• Advanced Cancer
• Colorectal Neoplasms
• COVID-19
• Diagnosis
• Disease
• Liver Neoplasms
• Neoplasm, Liver
• Neoplasms
• Neoplasms Pancreatic
• Neoplasms, Colorectal

Locations

Country	Name	City	State
France	Blanc-Bisson Christele	Bordeaux

Sponsors (1)

Lead Sponsor	Collaborator
University of Bordeaux

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	time from date of first symptoms of cancer to the date of first MDT	time from date of first symptoms of cancer to the date of first MDT	DAYS
Secondary	time from date of first symptoms to date of first consultation with a general practitioner,	time from date of first symptoms to date of first consultation with a general practitioner,	DAYS
Secondary	time from date of first symptoms to first imaging or specific examination,	difficulties in referral to imaging,	DAYS
Secondary	time from date of first symptoms to consultation with a specialist,	difficulties in referral to a specialist,	DAYS
Secondary	stage of pathology by type of cancer,	stage of pathology by type of cancer according to TNM classification (tumor, node, metastatic status)	at inclusion
Secondary	frequency of different types of cancer,	PERCENTAGE of each type of cancers in this study	at inclusion
Secondary	overall survival.	overall survival.	MONTHS, time from from date of first symptoms to date of death